ABLYNX INITIATES PHASE I FOR ALX-0141 (ANTI-RANKL)
(Thomson Reuters ONE) - GHENT, Belgium, 14 December 2009 - Ablynx [Euronext Brussels: ABLX]announced today that it has initiated a double-blind, randomised,placebo-controlled Phase I study with ALX-0141, a Nanobody® targetingReceptor Activator of Nuclear Factor kappa B Ligand (RANKL), inhealthy postmenopausal women.RANKL is involved in the production of osteoclasts, a type of cellresponsible for the destruction of bone (bone resorption). Undernormal physiological circumstances there is a delicate balancebetween bone formation and bone resorption, however, a disturbance inthis balance can lead to excessive osteoclast activity and bone loss.An anti-RANKL Nanobody has the potential to inhibit this process andmay have therapeutic application in the treatment of degenerativebone diseases, such as post-menopausal osteoporosis (PMO), rheumatoidarthritis and cancer driven bone deterioration.The Phase I study will investigate the safety, tolerability,pharmacokinetics and pharmacodynamics of a single subcutaneousinjection of ALX-0141. In addition, the study will measure importantbone biomarkers to provide an early indication of efficacy. Ablynxwill recruit up to 42 postmenopausal women, who represent the initialtarget population for ALX-0141 in PMO.Dr Edwin Moses, CEO and Chairman at Ablynx, commented: "We aredelighted to advance ALX-0141 into the clinic within just 3.5 yearsof initiating this programme. There are now four Nanobodies inclinical trials including Pfizer's anti-TNF-alpha Nanobody whichentered Phase II in September 2009 in patients with rheumatoidarthritis." -ends-About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.comFounded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceuticalcompany focused on the discovery and development of Nanobodies, anovel class of therapeutic proteins based on single-domain antibodyfragments, for a range of serious and life-threatening humandiseases. The Company currently has over 230 employees. Ablynxcompleted a successful IPO on Euronext Brussels [ABLX] on 7 November2007.For more information, please contact:College Hill Life Sciences - for International media enquiries:Sue Charles, Justine Lamondt: +44 (0)20 7866 7857f: +44 (0)20 7866 7900e: ablynx(at)collegehill.comAblynx:Dr Edwin MosesChairman and CEOt: +32 (0)9 262 00 07m: +44 (0)7771 954 193 / +32 (0)473 39 50 68e: edwin.moses(at)ablynx.comEva-Lotta AllanChief Business Officert: +32 (0)9 262 00 75m: +32 (0)475 78 36 21 / +44 (0)7990 570 900e: eva-lotta.allan(at)ablynx.comhttp://hugin.info/137912/R/1361108/332347.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 14.12.2009 - 12:00 Uhr
Sprache: Deutsch
News-ID 1007945
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
London
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 109 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX INITIATES PHASE I FOR ALX-0141 (ANTI-RANKL)
"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
